1. McNeill AM, Rosamond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385–90.
2. Chen J, Gu D, Chen CS, Wu X. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. NDT 2007; 22 (4): 1100–6.
3. Tanaka H, Shiohira Y, Uezu Y et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney International 2006; 69: 369–74.
4. Isomaa B, Lahti K, Aimgren P. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9.
5. Cirillo M, Senigalliesi L, Laurenzi M et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking. The Gubbio Population Study. Arch Intern Med 1998; 158 (17): 1933–9.
6. Jones CA, Francis ME, Eberhardt MS et al. Microalbuminuria in the US population: 3rd National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445–59.
7. Knight EI, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003; 41: 588–95.
8. Pedrinelli R, Dell'Omo G, Di Bello V et al. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J of Human Hypertension 2002; 2: 79–89.
9. Sabharwal RK, Singh P, Arora MM et al. Incidence of microalbuminuria in hypertensive patients. Indian J Clin Biochem 2008; 23 (1): 71–5.
10. Wang TJ, Evans JC, Meigs JB, Rifai N. Low-Grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111: 1370–6.
11. Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14–8.
12. Шилов Е.М. Нефрология. Учебное пособие для послевузовского образования. М., 2007; сс. 13–15, 58–61, 599–612.
13. Atthobari J, Brantsma A, Gansevoort R et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. NDT 2006; 21 (11): 3106–14.
14. De Jong WP, Halbesma N, Gansevoort RT. Screening for early chronic kidney disease – what method fits best? NDT 2006; 21 (9): 2358–61.
15. Saydah S, Eberhardt M, Rios-Burrows N et al. Prevalence of chronic kidney disease and associated risk factors. US 1999–2004. JAMA 2007; 297: 1767–8.
16. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140 (3): 167–74.
17. Арутюнов Г.П., Оганезова Л.Г. Гиперфильтрация при артериальной гипертензии: механизм развития, методы выявления и пути коррекции. Сердце. 2009; 3: 131–7.
18. Арутюнов Г.П., Оганезова Л.Г. Гиперфильтрация и метаболический синдром. Системные гипертензии. 2009; 1: 67–71.
19. Tomaszwski M, Charchar FJ, Maric C et al. Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 2007; 71 (8): 816–21.
20. Диагностика и лечение артериальной гипертонии. Рекомендации РМОАГ/ВНОК. 4-й пересмотр, 2010.
21. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностики и лечению метаболического синдрома (2-й пересмотр). Кардиоваскулярная терапия и профилактика. 2009; 8 (6).
22. Geluk CA, Asselbergs FW, Hillege HL et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart J 2005; 26 (13): 1314–20.
23. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–36.
24. Cushman DW, Wang FL, Fung WC et al. Differentiation of angiotensin converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294–307.
25. Napoli C, Sica V, de Nigris F et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148 (1): e5.
26. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–50.
27. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003; 482 (1–3): 95–9.
28. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332 (2): 80–5.
29. Морозова Т.Е., Шилов Е.М., Белобородова А.В. Хроническая болезнь почек и метаболический синдром. Возможности фармакологической коррекции. Сеченовский вестник. 2010; 2 (2): 56–63.
30. Морозова Т.Е., Андрущишина Т.Б., Ошорова С.Д. Оптимизация фармакотерапии артериальной гипертензии у больных метаболическим синдромом – возможности зофеноприла. Рос. кардиол. журн. 2011; 4 (90): 63–8.

Т.Е.Морозова 

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ, Москва